This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Osiris Therapeutics Takes a Bumpy Ride

Osiris Therapeutics (OSIR - Get Report) hit a snag Tuesday in its quest to develop new stem-cell therapies when a study for a knee-repairing drug came up lame.

In a proof-of-concept study, Osiris injected a mixture of adult stem cells called Chondrogen into the knees of patients who had a torn or damaged meniscus, which is the spongy, shock-absorbing cartilage between the tibia and femur.

It was hoped that stem cells in Chondrogen would implant in the knee and regenerate into new meniscus tissue. But after six months, patients given Chondrogen showed no increase in meniscus volume compared to patients given a sham injection, the company reported.

On Tuesday, Osiris shares fell more than 10%, but had regained some of that loss on Wednesday; the stock was recently up 1.95% to $18.81.

The Chondrogen setback isn't the end of the road for Osiris. The Baltimore-based company has another, more advanced, stem-cell therapy in phase III studies, the last step before potentially seeking FDA approval. As such, the company is much further along than its stem-cell competitors. And Osiris derives its stem cells from adult bone marrow, so it sidesteps the ethical controversy around the use of embryonic stem cells.

But the disappointing data also should remind investors that stem-cell research, while groundbreaking and cool, is still very risky business. And Osiris is no exception.

The Osiris story centers around mesenchymal stem cells (MSCs), which are capable of differentiating into tissues that provide rigidity or stability in the body -- bone, cartilage, fat, tendon or muscle. MSCs may also possess anti-inflammatory properties and appear not to activate an immune response when transplanted into an unrelated or unmatched host.
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
OSIR $16.50 -2.65%
AAPL $111.79 0.17%
FB $94.12 -0.15%
GOOG $652.30 0.87%
TSLA $219.25 1.70%


Chart of I:DJI
DOW 17,081.89 -49.97 -0.29%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,796.6090 -42.0340 -0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs